A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.
UCI's Dr. Michael Demetriou, Ani Grigorian and others found that oral
N-acetylglucosamine (GlcNAc), which is similar to but more effective
than the widely available glucosamine, inhibited the growth and function
of abnormal T-cells that in MS incorrectly direct the immune system to
attack and break down central nervous system tissue that insulates
nerves.
Study results appear online in The Journal of Biological Chemistry.
Earlier this year, Demetriou and colleagues discovered that
environmental and inherited risk factors associated with MS - previously
poorly understood and not known to be connected - converge to affect
how specific sugars are added to proteins regulating the disease.
"This sugar-based supplement corrects a genetic defect that induces
cells to attack the body in MS," said Demetriou, associate professor of
neurology and microbiology & molecular genetics, "making metabolic
therapy a rational approach that differs significantly from currently
available treatments."
Virtually all proteins on the surface of cells, including immune cells
such as T-cells, are modified by complex sugar molecules of variable
sizes and composition. Recent studies have linked changes in these
sugars to T-cell hyperactivity and autoimmune disease.
In mouse models of MS-like autoimmune disease, Demetriou and his team
found that GlcNAc given orally to those with leg weakness suppressed
T-cell hyperactivity and autoimmune response by increasing sugar
modifications to the T-cell proteins, thereby reversing the progression
to paralysis.
The study comes on the heels of others showing the potential of GlcNAc
in humans. One reported that eight of 12 children with
treatment-resistant autoimmune inflammatory bowel disease improved
significantly after two years of GlcNAc therapy. No serious adverse side
effects were noted.
"Together, these findings identify metabolic therapy using dietary
supplements such as GlcNAc as a possible treatment for autoimmune
diseases," said Demetriou, associate director of UCI's Multiple
Sclerosis Research Center. "Excitement about this strategy stems from
the novel mechanism for affecting T-cell function and autoimmunity - the
targeting of a molecular defect promoting disease - and its
availability and simplicity."
He cautioned that more human studies are required to assess the full
potential of the approach. GlcNAc supplements are available over the
counter and differ from commercially popular glucosamine. People who
purchase GlcNAc should consult with their doctors before use.
Tuesday, October 4, 2011
Multiple Sclerosis Attacks Suppressed By Glucosamine-Like Supplement
12:32 PM
m, New MS Treatment?